Download for iPhone

The science, plainly

We read the trials so you don't have to. Dosing, rotation, side effects - summarized from published studies and prescribing information, updated regularly. Not medical advice.

ARCHIVE

Latest articles

2026-09-09Semaglutide and Alzheimer's: what the EVOKE trial foundCognitive healthRead ->
2026-09-08Tirzepatide alone for diabetes: what SURPASS-1 foundType 2 diabetesRead ->
2026-09-06Mounjaro and birth control: what the FDA label says about drug interactionsDrug interactionsRead ->
2026-09-06Tirzepatide vs. semaglutide: what the SURPASS-2 trial foundType 2 diabetesRead ->
2026-09-04Mounjaro in teens: what the SURPASS-PEDS trial foundAdolescentsRead ->
2026-09-04Tirzepatide and gallbladder disease: what the safety data showSafetyRead ->
2026-09-03Stopping tirzepatide: what SURMOUNT-4 found about weight regain and heart riskDiscontinuationRead ->
2026-09-01Mounjaro's thyroid warning: what the data actually showSafetyRead ->
2026-08-31Tirzepatide after lifestyle intervention: what SURMOUNT-3 foundWeight plateauRead ->
2026-08-28Tirzepatide and diabetes: what the SURMOUNT-2 trial foundType 2 diabetesRead ->
2026-08-28Tirzepatide for weight loss: what the SURMOUNT-1 trial foundWeight lossRead ->
2026-08-26Tirzepatide and MASH: what the SYNERGY-NASH trial foundLiver diseaseRead ->
2026-08-25Oral semaglutide and heart risk: what the SOUL trial foundOral GLP-1Read ->
2026-08-25Tirzepatide and heart failure: what the SUMMIT trial foundHeart failureRead ->
2026-08-23Semaglutide and walking distance in peripheral artery disease: the STRIDE trialPeripheral artery diseaseRead ->
2026-08-22Semaglutide and NAION: what the eye risk data showEye safetyRead ->
2026-08-20Tirzepatide vs. semaglutide: what the SURMOUNT-5 head-to-head trial foundHead-to-headRead ->
2026-08-19GLP-1s before surgery: what the perioperative guidance saysPerioperativeRead ->
2026-08-19Zepbound and sleep apnea: what the SURMOUNT-OSA trial foundSleep ApneaRead ->
2026-08-19Semaglutide and knee osteoarthritis: what the STEP 9 trial foundOsteoarthritisRead ->
2026-08-17Tirzepatide and heart outcomes: what SURPASS-CVOT foundCardiovascularRead ->
2026-08-15Orforglipron: what the ATTAIN-1 trial showedOral GLP-1Read ->
2026-08-14Semaglutide and weight loss: what the STEP 1 trial showedWeight lossRead ->
2026-08-13Retatrutide: what the TRIUMPH-1 trial showed for weight lossInvestigational agentsRead ->
2026-08-11Semaglutide and alcohol use disorder: what the first randomized trial foundAlcohol use disorderRead ->
2026-08-10Tirzepatide and sleep apnea: what SURMOUNT-OSA foundSleep apneaRead ->
2026-08-09CagriSema: what the REDEFINE-1 trial showed for combination therapyCombination therapyRead ->
2026-08-07Semaglutide and heart health: what the SELECT trial showedCardiovascularRead ->
2026-08-06Semaglutide for MASH: what the ESSENCE trial actually showedLiver diseaseRead ->
2026-08-04Semaglutide's kidney effect: what the FLOW trial foundKidney diseaseRead ->
2026-08-04The first oral GLP-1 pill, explained: what Foundayo's ATTAIN-1 trial showedOral GLP-1Read ->
2026-08-03What happens when you stop GLP-1 therapy: the weight regain dataDiscontinuationRead ->
2026-08-01Semaglutide vs. tirzepatide: what the lean mass data showBody compositionRead ->
2026-08-01GLP-1 dose titration: what the trials actually showDosingRead ->
2026-08-01Why injection site rotation matters: the lipohypertrophy problemRotationRead ->

New articles published regularly. Sourced from peer-reviewed trials, FDA/EMA prescribing information, and manufacturer instructions for use. This page is a support and reference tool - always confirm changes to your regimen with your prescriber.